Follistatin 344 (1mg) is a recombinant protein supplied exclusively for controlled laboratory research. It is intended for in-vitro analytical testing, protein-binding assays, and experimental research involving activin, myostatin, and related transforming growth factor beta (TGF-β) superfamily signaling systems.
Follistatin 344 may be incorporated into qualified laboratory protocols examining protein-protein interactions, ligand-binding activity, biochemical characteristics, and growth-regulatory signaling mechanisms. Research applications should be conducted using validated controls, appropriate analytical methods, and documented experimental conditions.
Each vial contains 1mg of lyophilized research material. Lot-specific analytical documentation is available through the NordSci Peptides Certificate of Analysis library. Researchers should consult the applicable COA for reported identity, purity, and testing information before beginning an experiment.
NordSci Peptides uses independent analytical testing to document the identity and purity of its research materials. Available testing documentation may include high-performance liquid chromatography, mass spectrometry, or other methods identified on the applicable lot-specific COA.
The primary concern for peptide researchers today is product purity. Nord-sci guarantees our product purity by performing independent testing of our products and providing those certifications for our customers in our product descriptions.
THIS PRODUCT IS NOT INTENDED TO TREAT, CURE OR DIAGNOSE ANY CONDITION OR DISEASE AND IS NOT FOR HUMAN CONSUMPTION. ALL PRODUCTS OFFERED ARE INTENDED FOR LABORATORY RESEARCH USE ONLY.
All products are produced using lyophilization (freeze-drying), a preservation method that allows peptides to remain fully stable during shipping for approximately 3-4 months. Once a peptide has been reconstituted with bacteriostatic water, it must be refrigerated to maintain integrity. After reconstitution, peptides typically remain stable for up to 30 days when stored properly.
Lyophilization, also referred to as cryodesiccation, is a specialized dehydration process in which peptides are first frozen and then exposed to a low-pressure environment. This causes the water within the vial to transition directly from a solid to a vapor (sublimation), leaving behind a dry, crystalline white material known as a lyophilized peptide. In this powdered form, peptides may be safely stored at room temperature until they are ready to be reconstituted with bacteriostatic water.
After delivery, peptides should be protected from heat and light. If use is expected within the near future (whether days, weeks, or a few months) refrigerated storage below 4°C (39°F) is generally sufficient. Lyophilized peptides are commonly stable at room temperature for several weeks or longer, making short-term ambient storage acceptable when use is anticipated within that timeframe.
For extended storage, ranging from several months to multiple years, freezing is strongly recommended. Storage at -80°C (-112°F) offers optimal long-term stability and helps preserve peptide structure and quality over time.
For more detailed guidance on peptide handling and storage best practices, please refer to the resource below:
Follistatin 344 (1mg) is a recombinant research protein intended for controlled laboratory investigation of activin-binding proteins, myostatin-associated signaling systems, and other molecular interactions involving members of the transforming growth factor beta (TGF-β) superfamily.
The FST344 reference precursor contains 344 amino acids. Public protein databases report a theoretical mass of approximately 38 kDa for the human reference precursor. The measured characteristics of a recombinant research material may vary according to its expression system, processing, glycosylation state, formulation, and analytical method. Researchers should consult the lot-specific Certificate of Analysis for product-specific specifications.
Follistatin proteins are studied as extracellular ligand-binding proteins. Controlled experiments may examine their interactions with activin, myostatin, and related signaling molecules through binding assays, biochemical characterization, expression analysis, and other validated laboratory methods.
Follistatin 344 (1mg) – Research Specifications:
| Compound | Follistatin 344 |
| Quantity | 1mg per vial |
| Compound Type | Recombinant research protein |
| Reference Precursor Length | 344 amino acids |
| Reference Precursor Mass | Approximately 38 kDa; consult lot-specific documentation for the supplied material |
| Sequence | Reference sequence available through UniProt P19883 and NCBI NP_037541.1; verify the supplied recombinant construct against lot-specific documentation |
| Form | Lyophilized research material |
| Purity / Identity | Refer to the applicable Certificate of Analysis for lot-specific analytical findings |
| Analytical Documentation | Lot-specific Certificate of Analysis available |
| Storage Conditions | Store sealed under the conditions stated on the product label or lot-specific documentation; protect from heat, light, and moisture |
| Intended Application | Controlled in-vitro laboratory research and analytical testing |
| Research Use Only | Not for human or animal consumption or use |
Follistatin 344 is the longer human follistatin precursor isoform encoded by the FST gene. Its reference sequence contains multiple follistatin and Kazal-like domains relevant to its molecular structure and ligand-binding characteristics.
Laboratory research involving follistatin commonly examines its binding relationships with activin, myostatin, and other members of the TGF-β superfamily. These investigations may use purified-protein systems, cell-free assays, cultured-cell models, or other controlled in-vitro research platforms.
Follistatin 344 may also be used as a reference material in studies comparing protein isoforms, binding affinity, domain structure, ligand specificity, protein expression, and biochemical behavior. Experimental observations should be interpreted within the defined conditions and limitations of the research model.
This product is not supplied for clinical investigation, personal experimentation, veterinary procedures, or use in humans or animals.
Important Research Notice: NordSci Peptides provides lot-specific analytical documentation for its research materials. Researchers should review the applicable Certificate of Analysis to confirm the reported specifications for the received lot.
THIS PRODUCT IS INTENDED FOR LABORATORY RESEARCH USE ONLY. NOT FOR HUMAN OR ANIMAL CONSUMPTION. NOT INTENDED TO DIAGNOSE, TREAT, CURE, OR PREVENT ANY DISEASE OR CONDITION.
Controlled laboratory studies may use Follistatin 344 to examine protein-binding interactions involving myostatin and related regulatory signaling components. Applicable experimental methods may include binding assays, comparative protein analysis, and pathway-specific in-vitro models.
This research context does not establish or imply a therapeutic, performance-related, or physiological outcome.
Follistatin 344 may be studied in experimental systems designed to characterize activin-binding activity, ligand specificity, receptor-associated signaling, and other molecular interactions involving activin-family proteins.
Researchers should use appropriate controls and validated analytical methods when comparing experimental conditions or protein isoforms.
Qualified laboratories may investigate Follistatin 344 within controlled models involving growth-regulatory signaling, gene-expression responses, ligand availability, and extracellular protein interactions.
The product is intended solely as a laboratory research material. It is not intended to produce or evaluate outcomes in humans or animals.
Follistatin 344 may be incorporated into in-vitro studies examining protein structure, domain organization, ligand-binding characteristics, molecular recognition, and signaling systems associated with developmental biology.
References to tissue development describe the experimental subject matter and do not represent claims regarding tissue repair, regeneration, recovery, or therapeutic application.
Follistatin 344 (1mg) should be handled only by trained personnel using established procedures for recombinant research proteins. Laboratories should maintain appropriate environmental controls, personal protective equipment, sample-identification practices, and experimental records.
The material should remain properly labeled throughout receipt, storage, preparation, testing, and disposal. Cross-contamination should be minimized through validated laboratory procedures and dedicated handling equipment where appropriate.
Storage history, assay conditions, reagent compatibility, preparation methods, equipment calibration, and analytical controls should be documented to facilitate reproducibility. Any prepared laboratory solutions should be managed according to the institution’s validated research protocol.
Protocol Design Considerations: Experimental findings may be influenced by the recombinant construct, formulation, concentration, assay format, cell line, reagent compatibility, incubation conditions, analytical method, and other laboratory variables. Researchers are responsible for establishing suitable controls and determining whether the material is appropriate for a specific in-vitro protocol.
This information is provided exclusively as a laboratory research reference. No dosing, administration, clinical-application, or personal-use guidance is provided.
Lot-specific analytical documentation is available for Follistatin 344 (1mg). The applicable Certificate of Analysis may report information concerning identity, purity, analytical methods, and other batch-specific findings.
Researchers should match the lot number printed on the product label with the corresponding COA before incorporating the material into a laboratory protocol. The COA should be retained with the laboratory’s procurement, inventory, and experimental records.
Analytical documentation characterizes the tested research material under the stated methods and conditions. It does not constitute clinical validation, therapeutic approval, or authorization for human or animal use.
Qualified laboratories sourcing Follistatin 344 should evaluate product identity, lot traceability, analytical documentation, storage requirements, and supplier quality-control procedures.
NordSci Peptides supplies Follistatin 344 (1mg) exclusively as a research-use-only material. Lot-specific documentation is available to assist laboratories with procurement review, inventory management, and experimental recordkeeping.
IMPORTANT: Follistatin 344 (1mg) is supplied exclusively for controlled laboratory research. It is not a drug, food, cosmetic, dietary supplement, or medical product. It is not approved or intended for human consumption, animal consumption, diagnostic procedures, therapeutic applications, veterinary use, or any form of in-vivo administration.
